Clinical Trial Update: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating Orelabrutinib for secondary progressive multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Zenas BioPharma (USA), LLC | Conditions: Secondary Progressive Multiple Sclerosis | Phase 3 | Status: RECRUITING